Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Baucus “Expects Answers” On Sen. Grassley’s FDA Inquiries

Executive Summary

The inquiries by Senate Finance Committee Ranking Minority Member Chuck Grassley, R-Iowa, into FDA carry the imprimatur of committee chairman Max Baucus, D-Mont., even though the two senators traded leadership positions with the start of the 110 Congress, Baucus says

You may also be interested in...



Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity

The House Energy and Commerce Committee's inquiries into Sanofi-Aventis' Ketek could be a jumping-off point for a wide-ranging congressional look into the integrity of clinical trials and oversight of companies involved in those trials

Profile Of A Drug Safety Scandal: Avandia Appears Headed Down Familiar Path

With FDA planning an advisory committee review and Congress calling for hearings, the detection of a cardiovascular safety signal for GlaxoSmithKline's type 2 diabetes therapy Avandia has all the hallmarks of a classic drug safety scandal

Profile Of A Drug Safety Scandal: Avandia Appears Headed Down Familiar Path

With FDA planning an advisory committee review and Congress calling for hearings, the detection of a cardiovascular safety signal for GlaxoSmithKline's type 2 diabetes therapy Avandia has all the hallmarks of a classic drug safety scandal

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel